跳至主要内容
临床试验/DRKS00004794
DRKS00004794已完成不适用

Prospective observational study to assess the efficacy and tolerability of axiplatin® using different timing regimens and doses in clinical practice in patients with stage III colon carcinoma (Dukes C) or metastatic colorectal carcinoma (short title: FREDOS). - FREDOS

AxioNovo GmbH0 个研究点目标入组 575 人开始时间: 2013年3月6日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AxioNovo GmbH
入组人数
575

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
one 至 one(—)
性别
All

入选标准

  • Patients with stage III colon carcinoma (Dukes C) for whom therapy with axiplatin® is indicated according to the SmPC.
  • - Patients with metastatic colorectal cancer for whom therapy with axiplatin® is indicated according to the SmPC.
  • - Age: older than 18 years
  • - Axiplatin is used in therapy.
  • - A hand-dated and signed informed consent is available.
  • - Therapy was selected independent of potential study inclusion.

排除标准

  • - Contraindications to the use of Epirubicin LIV Pharma according to the SmPC.
  • - The current therapy was started more than 12 weeks ago.
  • - The patient is participating in a clinical trial at the same time.

研究者

发起方
AxioNovo GmbH

相似试验